Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE

Pfizer

The teams at Moderna, Pfizer and BioNTech recount the historic race to develop Covid-19 vaccines in a newly released documentary by CNBC.

A race against Covid: How Moderna and Pfizer-BioNTech developed vaccines in record time

Metallic particle is believed to be a contaminant found in a batch of Moderna Inc's (NASDAQ: MRNA) COVID-19 vaccines delivered to Japan, Japanese public broadcaster NHK reported, citing sources at the health ministry. Japan suspended the use of 1.63 million doses more than a week after the domestic distributor, Takeda Pharmaceutical Co Ltd (NYSE: TAK), received reports of contaminants in some vials.

Suspected Metallic Particles Behind Moderna's Japan COVID-19 Jab Contamination: Reuters

Moderna (MRNA) completes rolling submission of BLA to the FDA seeking full approval of its COVID-19 vaccine candidate, mRNA-1273, in the United States.

Moderna (MRNA) Seeks Full FDA Approval for COVID-19 Vaccine

Japan suspended the use of more than 1.6 million doses of the Moderna vaccine Thursday following reports of contaminated vials.

Japan pulls 1.6 million Moderna vaccine doses over contamination concerns

Japan's health ministry has suspended the use of 1.63 million doses of Moderna's Covid-19 vaccine over contamination fears, according to reports. But the biotech said no safety issues have been identified to date.

Japan Halts 1.6M Doses of Moderna Vaccine Over Contamination Concerns

Moderna's sales prospects beyond 2021 continue to improve.

The Most Important Thing to Know About Moderna's Expanded Canadian Supply Deal

Moderna's COVID-19 vaccine technology has rewarded investors with serious gains. What's next for the stock?

Moderna Is Up 500% in 12 Months. Can It Keep Going?

Drugmaker Moderna said it withheld the supply of the shots after contamination of vials with particulate matter.

Japan Halts Use Of 1.63 Million Moderna Doses Over Contamination Concerns

More than a million doses of Moderna Inc's (NASDAQ: MRNA) coronavirus vaccine have been taken out of circulation in Japan after reports of contamination emerged, Nikkei Asia reported Wednesday. What Happened: Nearly 1.6 million doses were put out of use in Japan, as per the country's Ministry of Health, Labor and Welfare, reported Nikkei Asia.

Moderna Withdraws 1.6M COVID-19 Vaccine Doses In Japan Over Contamination Concerns

I have maintained that the need for vaccines and booster shots to combat the tragic SARS-CoV-2 pandemic will be required for years as the endemic phase is entered.

COVID-19 Vaccines And Booster Shots Will Be Required For Years, Suggesting That Moderna Will Significantly Exceed Projections

Moderna, Inc. (NASDAQ: MRNA) shares are about 18% off the recent high of $497.49 hit on Aug. 10. The Rally That Petered Out: Moderna stock took a leg up in early August just ahead of the release of the company's quarterly results.

Moderna Sets R&D Day For Sept. 9: Can Event Kickstart Sagging Stock?

Agios Pharmaceuticals

Exelixis

Johnson & Johnson

Novavax

SAGE Therapeutics

Vertex Pharmaceuticals

Biotech stocks are worth considering. Risk aside, big pharma firms can still produce big pharma returns at the end of the day.

7 Best Biotech Stocks to Buy in 2021 with Huge Upside

The potential for a third shot is giving them a boost.

Why Shares of Moderna and Novavax Are Higher This Morning

Moderna Inc (NASDAQ: MRNA) has completed the rolling submission process for its marketing application to the FDA, seeking full licensure of its COVID-19 vaccine. The application is for active immunization to prevent COVID-19 in individuals 18 years of age and older.

Moderna Concludes US Filing For COVID-19 Shot

Best Buy

Apple

Northern Trust

Q.ai runs daily factor models to get the most up-to-date reading on stocks and ETFs. Today, our deep-learning algorithms have identified Best Buy among others.

Best Buy Among Today's Trending Stocks As Indices Trend Upward

Shares of Moderna Inc. MRNA, +3.39% rallied 4.0% in morning trading Wednesday after the biotechnology company said it has completed the submission to the Food and Drug Administration for its Biologics License Application (BLA) for the "full licensure" of its COVID-19 vaccine, for people 18 years old and older. "This BLA submission for our COVID-19 vaccine, which we began in June, is an important milestone in our battle against COVID-19 and for Moderna, as this is the first BLA submission in our company's history," said Chief Executive Stéphane Bancel.

Moderna completes BLA submission for full approval of COVID-19 vaccine

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna completes submission of Biologics License Application to the U.S. Food and Drug Administration for its COVID-19 vaccine.

Moderna Completes Submission of Biologics License Application to the U.S. Food and Drug Administration for its COVID-19 Vaccine

Deere & Company

NVIDIA

Regeneron Pharmaceuticals

We have narrowed down our search to six stocks that are members of any of the three major indexes. These are: MRNA, NVDA, TJX, AAPL, DE and REGN.

6 Must-Buy Corporate Giants As Major Indexes Hit Record High

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna to host virtual R&D Day on Thursday, September 9, 2021.

Moderna to Host Virtual R&D Day on Thursday, September 9, 2021

The euphoria over full FDA approval of the Pfizer-BioNTech vaccine appears to be waning.

Why Pfizer, BioNTech, Moderna, and Novavax Stocks Are Sinking Today

AMC Entertainment

Coinbase

FuelCell Energy

Canoo

Plug Power

Romeo Power

Starbucks

Trillium Therapeutics

Tesla

So what did the stock market do today? Investors cheered on Pfizer stock and rallied behind infrastructure plays.

What Did the Stock Market Do Today, Aug. 23? 3 Big Stories to Catch Up On.

A major regulatory approval sparked a rally in coronavirus vaccine stocks.

Why Pfizer, BioNTech, and Moderna Stocks Jumped Today

Alibaba

Pfizer, Moderna, Nvidia and Alibaba were our top stock trades for Tuesday. Now, let's get a look at the charts as the market hits new highs.

4 Top Stock Trades for Tuesday: PFE, MRNA, NVDA, BABA

UiPath

Coatue Management recently disclosed its 13F portfolio updates for the second quarter of 2021, which ended on June 30.

Philippe Laffont's Firm Buys UiPath, Adds to Moderna

Moderna, Inc. (NASDAQ: MRNA) shares were advancing strongly Monday on a sympathy move. What Happened: Moderna shares, which peaked at $497.49 on Aug. 10, have since pulled back.

News for Moderna Stock (MRNA)